- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Living Life With Metastatic Breast Cancer From a Male Perspective
In this episode of Managed Care Cast, we speak with a male patient with breast cancer who was diagnosed with metastatic disease in 2016 about how he lives his life and what he wants people to know about this rare cancer.
Metastatic breast cancer is the most advanced stage of breast cancer; it is treatable but not curable. Men with breast cancer comprise less than 1% of all patients with the disease, and most of their treatments are based on study results seen among female patients. This year alone, experts predict that 276,480 women and 2620 men will receive a breast cancer diagnosis.
The American Journal of Managed Care® spoke recently with Kirby Lewis of West Virginia. Kirby was a stage 2 breast cancer survivor, for which he had a mastectomy in 2012, prior to receiving a diagnosis of metastatic breast cancer (MBC) in 2016. He is 1 of 9 patients with MBC who serve as representatives of “Facing MBC Together” from Athenex Oncology.
In this interview, he describes his philosophy about living life to the fullest and what he wants people to know about male breast cancer.
Listen above or through one of these podcast services:
Trastuzumab Biosimilar Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers
December 5th 2023EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.
Read More
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Read More
